Suriya Jayawardena, MD
Interventional Cardiology · Fayetteville, NCNPI 1336338268
Payments from drug & device makers
What this record shows
This record is dominated by other: $48,667 of the $56,455 with a category attached, or 86.2%. Angiodynamics, Inc. accounts for 89.9% of it on its own, with 41 other manufacturers making up the rest. Reporting peaked in 2024 at $40,309 and has fallen 74.9% since, to $10,113 in 2025.
Across 330 payments — averaging $171.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$51K
- Bard Peripheral Vascular, Inc.$995
- Novartis$763
- Novo Nordisk$439
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$345
- Abbott$307
- plus $3K from 36 others
What the payments were for
- Travel & lodging$1,7003%
- Food & beverage$6,08811%
- Other$48,66786%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$48,667
- ELIQUIS$114
- Diamondback Peripheral$109
How this compares
$56,455 in reported general payments places this provider in the 85th percentile of 180 interventional cardiology providers in North Carolina.
See all interventional cardiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 133 | $131,624 |
| OzempicSemaglutide | 102 | $131,326 |
| EliquisApixaban | 66 | $64,559 |
| EntrestoSacubitril/Valsartan | 33 | $47,218 |
| RybelsusSemaglutide | 16 | $39,819 |
| TrulicityDulaglutide | 21 | $34,148 |
| JardianceEmpagliflozin | 28 | $25,187 |
| LinzessLinaclotide | 30 | $21,022 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $20,765 |
| MounjaroTirzepatide | 17 | $20,641 |
| Praluent PenAlirocumab | 14 | $15,434 |
| BrilintaTicagrelor | 23 | $12,816 |
| Diclofenac Potassium | 16 | $10,576 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 384 | $10,286 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 16 | $10,247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $439 | $171,145118 claims |
| PfizerEliquis | $20 | $64,55966 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $73 | $54,78938 claims |
| NovartisEntresto | $763 | $47,21833 claims |
| Boehringer IngelheimJardiance | $85 | $25,18728 claims |
| AbbVieLinzess | $253 | $21,02230 claims |
| AstraZenecaBrilinta | $241 | $12,81623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 180 interventional cardiology providers in North Carolina.
Other interventional cardiology in Fayetteville
- Frank FedeleFayetteville$36K
- Matthew DakaFayetteville$16K
- Michael MillerFayetteville$10K
- George AdamsGarner$4.1M
- Paul MahoneyGreenville$1.7M
- Ravish SacharRaleigh$1.6M
- Patrick SimpsonPinehurst$579K
- Ronald UszenskiMooresville$495K
- Oluseun AlliCharlotte$485K
- Matthew CavenderChapel Hill$453K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.